Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
When combined correctly, the synergistic effects can create some truly extraordinary outcomes
PLoS One 12 , e0171781 (2017)
Differentiation 84(1):416 Uenaka R, Kuwajima M, Ono A, Matsuzawa Y, Hayakawa J, Inohara N, Kagawa Y, Ohta S (1996) Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice
The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability resulting in approximately three times greater potency than IGF-1, with a significantly longer half-life of about 2030 hours relative to IGF-1s half-life of about 1215 hours
The FDA target action date is April 10, 2026
